Pacira BioSciences' Upcoming Financial Report
Pacira BioSciences, Inc. (NASDAQ: PCRX), renowned for its innovative approaches in pain management through non-opioid therapies, is gearing up to disclose its financial performance for the fourth quarter and the entire year of 2024. The company will release these anticipated results after the U.S. market closes on Thursday, February 27, 2025. A crucial aspect of this announcement will be the accompanying live conference call scheduled for 4:30 p.m. ET, where insights and discussions will follow the results presentation.
Engagement Opportunity for Investors
Investors and stakeholders interested in delving deeper into the company’s performance are encouraged to register for a question-and-answer session to engage with the management. The pre-registration process has been set up to ensure that participants receive all necessary dial-in details and a personal identification number for seamless access to the live call. Moreover, the conference call will be accessible as a webcast for those unable to join in real-time, with a replay available on the Pacira website for about two weeks after the event.
About Pacira BioSciences
Pacira is at the forefront of developing advanced, non-opioid pain management therapies aimed at improving the quality of life for patients. The company has introduced three commercially available treatments that have revolutionized the treatment landscape. These include EXPAREL (bupivacaine liposome injectable suspension), designed for multifaceted surgical procedures; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), utilized for managing knee pain in osteoarthritis; and ioveraº, an innovative device that employs cold therapy for immediate and prolonged pain relief.
Investment Portfolio and Future Developments
Furthermore, Pacira is actively progressing the development of PCRX-201, a novel localized gene therapy with significant potential in addressing widespread diseases such as osteoarthritis. Such initiatives underline Pacira's commitment to pioneering effective healthcare solutions that alleviate pain without the reliance on opioids.
Current Market Context
As the healthcare sector continues to emphasize the reduction of opioid prescriptions, Pacira's innovative therapies stand out in the market. The company is positioning itself strategically to cater to an increasing demand for safer alternatives in pain management. The upcoming financial results are expected to shed light on the effectiveness of their initiatives and the overall performance of Pacira BioSciences.
Investor Communication and Transparency
Pacira BioSciences is dedicated to maintaining open lines of communication with its investors. The company's engagement through conference calls not only demonstrates its transparency but also helps in building a robust relationship with stakeholders who are invested in its journey and success.
Contact Information for Inquiries
For direct inquiries, interested parties can reach out to:
Investor Contact: Pacira BioSciences, Inc. Christian Pedetti, (973) 254-4387 Christian.Pedetti@pacira.com
Frequently Asked Questions
What financial results will Pacira report?
Pacira is set to report its fourth quarter and annual financial results for the year ending December 31, 2024.
When is the conference call scheduled?
The live conference call will take place on February 27, 2025, at 4:30 p.m. ET.
How can I participate in the Q&A session?
Listeners can pre-register for the Q&A session to receive dial-in information and a PIN number for access.
Will there be a replay of the conference call?
Yes, a replay of the conference call will be available on the Pacira website for approximately two weeks after the event.
What therapies does Pacira offer?
Pacira provides innovative non-opioid pain therapies, including EXPAREL, ZILRETTA, and ioveraº, aimed at transforming patient care.
